A Dose Finding Study to Investigate the Safety and Effectiveness of GSK1070806 in Adult Participants With Moderate to Severe Atopic Dermatitis

Summary

This study is parallel group, placebo-controlled dose-ranging study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of GSK1070806 in adult participants with moderate to severe Atopic Dermatitis (AtD), who have previously been treated with medicated topical treatments or a biologic therapy.

Timeline

Start

2023-11-16

Primary completion

2025-07-23

Completion

2025-07-23

Outcome

Outcome not reported

Stopped (Business): “Sponsor decision to early terminate the study based on the pre-defined futility criterion for efficacy. No safety concerns were identified.”

Drugs

Indications